Last reviewed · How we verify
LEVETIRACETAM
At a glance
| Generic name | LEVETIRACETAM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1999 |
Approved indications
Common side effects
- Asthenia
- Somnolence
- Headache
- Infection
- Dizziness
- Pain
- Pharyngitis
- Depression
- Nervousness
- Rhinitis
- Anorexia
- Ataxia
Key clinical trials
- Levetiracetam Three Times Daily in Epilepsy (PHASE3)
- Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases (PHASE2)
- Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT) (PHASE3)
- Levetiracetam for Persons at Risk for Alzheimer's Disease (PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly (PHASE2)
- B6 Administration for Levetiracetam-Associated Neurobehavioral Changes and Epilepsy (NA)
- Evaluation of Levetiracetam's Effectiveness and Tolerability for Treating Epilepsy in Older Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEVETIRACETAM CI brief — competitive landscape report
- LEVETIRACETAM updates RSS · CI watch RSS